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Chemokine (C-C motif) ligand 3 (CCL3), also known as macrophage inflammatory protein-1α, is a cytokine involved
in inflammation and activation of polymorphonuclear leukocytes. CCL3 has been detected in infiltrating cells and
tumor cells. Chondrosarcoma is a highly malignant tumor that causes distant metastasis. However, the effect of
CCL3 on human chondrosarcoma metastasis is still unknown. Here, we found that CCL3 increased cellular migration
and expression of matrix metalloproteinase (MMP)-2 in human chondrosarcoma cells. Pre-treatment of cells with
the MMP-2 inhibitor or transfection with MMP-2 specific siRNA abolished CCL3-induced cell migration. CCL3 has
been reported to exert its effects through activation of its specific receptor, CC chemokine receptor 5 (CCR5). The
CCR5 and AMP-activated protein kinase (AMPK) inhibitor or siRNA also attenuated CCL3-upregulated cell motility
and MMP-2 expression. CCL3-induced expression of MMP-2 and migration were also inhibited by specific inhibitors,
and inactive mutants of AMPK, p38 mitogen activated protein kinase (p38 or p38-MAPK), and nuclear factor κB
(NF-κB) cascades. On the other hand, CCL3 treatment demonstrably activated AMPK, p38, and NF-κB signaling
pathways. Furthermore, the expression levels of CCL3, CCR5, and MMP-2 were correlated in human
chondrosarcoma specimens. Taken together, our results indicate that CCL3 enhances the migratory ability of
human chondrosarcoma cells by increasing MMP-2 expression via the CCR5, AMPK, p38, and NF-κB pathways.
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Chondrosarcomas are the third most common bone tu-
mors, after myelomas and osteosarcomas. Chondrosarco-
mas are rapidly progressive, pathologically diverse, and
highly malignant, and to date, surgical resection remains
the primary treatment for these sarcomas. They also have
the potential for distant metastasis [1]. Therefore, better
strategies of treatment will ultimately require understand-
ing of the molecular mechanisms of the metastasis step of* Correspondence: chtang@mail.cmu.edu.tw
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targeting.
Metastasis is a multistage process that requires cancer
cells to escape from the primary tumor, survive in the
circulation, seed at distant sites, and grow. Metastasis in-
creases cell motility, induction of vascular and lymphatic
angiogenesis, and migration and invasion to other or-
gans [2]. The invasion of tumor cells is a complex,
multistage process. To facilitate cell motility, invading
cells need to change their cell-cell adhesion properties,
rearrange the extracellular matrix (ECM) environment,
suppress anoikis, and reorganize their cytoskeleton [3].
MMPs play important roles in these processes because
their proteolytic activities assist in the degradation of the
ECM and basement membranes [4,5]. In addition to
MMPs, cytokines, growth factors, and chemokines have. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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autocrine or paracrine pathways [6]. Previous studies
have demonstrated the expression of MMP-1, MMP-2,
MMP-3, MMP-9, and MMP-13 in human chondro-
sarcoma cells [7]. Among the all MMP enzymes, MMP-
2 (collagenase-2) is particularly interesting because of its
role in cartilage degradation via the breakdown of type II
collagen, the major collagen component of cartilage. It
has also been reported that MMP-2 plays a critical role
in ECM turnover and cell-cell interactions as well as me-
tastases of chondrosarcomas [8].
Chemokines are low-molecular weight secretory pro-
teins that can regulate the chemotaxis and the metabolic
activity of specific leukocyte subsets. Their production,
in general, is stimulated by pro-inflammatory cytokines,
growth factors, and by pathogenic stimuli arising in in-
flammatory tissues. In diseased tissues, different tumor
cell types trigger different complex chemokine networks
that influence the quality and quantity of immune-cell
infiltration and, consequently, the proliferation, survival,
spread, and angiogenic response of malignant cells [9].
CCL3, also known as macrophage inflammatory protein
1α (MIP-1α), is a pro-inflammatory cytokine belonging
to the CC chemokine subfamily and is a ligand for
CCR5, which stimulates chemotactic activities in a var-
iety of immune cells such as monocytes, lymphocytes,
macrophages [10,11]. CCL3 has also been implicated in
the regulation of cancer cell growth, angiogenesis and
metastasis of different tumors such as melanoma [12],
colorectal cancer [13], and renal cell carcinoma [14].
Epidemiological studies have shown that energy avail-
ability is associated with an increased risk of several
metabolic diseases such as obesity, hypertension, dia-
betes, and induced cancers [15,16]. Aberrant energy me-
tabolism may induce systemic and chronic inflammation
both at the cellular and whole-body levels, and hence
provide the microenvironment [17]. AMPK is a critical
regulator of glucose intake and energy balance and mod-
ulates energy regulation involved in glucose and lipid
metabolism [18,19]. On the other hand, AMPK has been
identified as a novel target in tumor cell migration and
invasion [20]. Despite this, the role of AMPK activation
in CCL3-mediated cancer migration has not been inves-
tigated in chondrosarcomas. In this study, we observed
that CCL3 increases the migration of human chondro-
sarcoma cells and upregulates the expression of MMP-2.
Furthermore, we observed that the CCR5 receptor, AMPK,




Anti-mouse and anti-rabbit IgG-conjugated horseradish
peroxidase, rabbit polyclonal antibodies specific for β-actin,AMPK, phospho(p)-AMPK (Thr172), p38, p-p38, inhibitor
of kappa B (IκB), p-IκBα, IκB kinase (IKKα/β) (Ser180/181),
NF-κB p65 subunit (p65), p-p65 (Ser536), and MMP-2;
control shRNA (sc-108060) and CCL3 shRNA (sc-44722-
SH) plasmids were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). AMPK inhibitors (Ara A and
compound C), p38 inhibitor (SB203580), IκB protease in-
hibitor (TPCK), NF-κB inhibitor (PDTC), and MMP-2 in-
hibitor were purchased from Calbiochem (San Diego,
CA). CCL3 and CCR5 monoclonal antibody (mAb) were
purchased from Abcam (Cambridge, MA). Met-RANTES
was purchased from R&D Systems (Minneapolis, MN,
USA). The p38 dominant-negative MAPK mutant was
provided by Dr. J. Han (Southwestern Medical Center,
Dallas, TX). The IKKα (KM) (K44A) and IKKβ (KM)
(K44A) mutants were gifted by Dr. H. Nakano (Juntendo
University, Tokyo, Japan). All other chemicals were pur-
chased from Sigma-Aldrich (St. Louis, MO).
Cell cultures
The human chondrosarcoma cell line (JJ012) was kindly
provided by the laboratory of Dr. Sean P. Scully (Univer-
sity of Miami School of Medicine, Miami, FL) and origi-
nated from Dr. Joel Block (Rush University Medical
Center, Chicago, Illinois). JJ012 cells were cultured in a
complete medium containing Dulbecco’s modified Ea-
gle’s medium (DMEM)/α-minimum essential medium
(α-MEM) supplemented with 10% fetal bovine serum
(FBS). The human chondrosarcoma cell line (SW1353)
was obtained from the American Type Culture Collec-
tion. SW1353 cells were cultured in a complete medium
containing DMEM supplemented with 10% FBS. All ex-
periments with cells were maintained at 37°C in a hu-
midified atmosphere of 5% CO2.
CCL3 shRNA or control shRNA plasmids were
transfected into JJ012 cells by using the transfection re-
agent, Lipofectamine 2000. At 24 h after transfection,
stable transfectants were selected with 10 μg/mL puro-
mycin (Life Technologies). The selection medium was
replaced every 3 days and 2 weeks after selection, and
puromycin-resistant cells and their clones were isolated.
Migration and invasion assay
The migration assay was performed using the Transwell
assay (Costar, Acton, MA; pore size, 8-μm) in 24-well
dishes. For the invasion assay, filters were precoated
with 30 μL Matrigel Basement Membrane Matrix (BD
Biosciences, Bedford, MA) for 30 min. The procedure
for both migration and invasion assays was as follows.
Before the migration assay was performed, cells were
pretreated for 30 min with different concentrations of
inhibitors, including the CCR5 mAb, compound C, Ara
A, SB208530, TPCK, PDTC, MMP-2 inhibitor, or vehicle
control (0.1% DMSO). Approximately 1 × 104 cells in
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chamber, and 300 μL of the same medium containing
CCL3 was placed in the lower chamber. The plates were
incubated for 24 h at 37°C in 5% CO2, and cells were
then fixed in methanol for 15 min and stained with
0.05% crystal violet in PBS for 15 min. Cells on the
upper side of the filters were removed with cotton-
tipped swabs, and the filters were washed with PBS.
Cells on the underside of the filters were examined and
counted under a microscope. Each clone was plated in
triplicate in each experiment, and each experiment was
repeated at least 3 times [3,21].
Wound-healing migration assay
For wound-healing migration assays, cells were seeded
on 12-well plates at a density of 1 × 105 cells/well in cul-
ture medium. At 24 h after seeding, the confluent mono-
layer of culture was scratched with a fine pipette tip, and
migration was visualized by microscopy. The rate of
wound closure was observed at the indicated times [22].
Zymographic analysis
Supernatants collected from JJ012 cell cultures were
mixed with sample buffer without reducing agents or
heating. Samples were loaded onto a 10% SDS-PAGE gel
containing 1 mg/ml gelatin and electrophoresed under
constant voltage. Subsequently, the gel was washed with
2.5% Triton X-100 to remove SDS, rinsed with 50 mM
Tris–HCl, pH 7.5, and then incubated overnight at room
temperature with a developing buffer (50 mM Tris–HCl,
pH 7.5, 5 mM CaCl2, 1 μM ZnCl2, 0.02% thimerosal,
and 1% Triton X-100). Zymographic activity was re-
vealed by staining with 1% Coomassie Blue.
Transfection of siRNAs or mutants
ON-TARGETplus siRNA targeting AMPKα1, AMPKα2
(The two catalytic subunit of AMPK; transfection of cells
with AMPKα1 or AMPKα2 siRNA inhibited AMPKα1
or AMPKα2 expression, respectively; Additional file 1:
Figure S1), MMP-2, and controls were purchased from
Dharmacon Research (Lafayette, CO, USA). Transient
transfection of siRNAs (10 nM) or dominant-negative
mutants (0.5 μg) was carried out using DharmaFECT1
transfection reagent or Lipofectamine 2000 (Invitrogen,
Carlsbad, CA), according to the manufacturer’s instruc-
tions, respectively.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qPCR)
analysis was carried out using TaqMan® one-step PCR
Master Mix (Applied Biosystems, Foster City, CA, USA).
Total complementary DNA (100 ng/25 μL reaction) was
mixed with sequence-specific primers and TaqMan®
probes according to the manufacturer’s instructions. Alltarget gene primers and probes were purchased com-
mercially, and GAPDH was used as the internal control
(Applied Biosystems). qPCR assays were carried out in
triplicate with a StepOnePlus sequence detection system.
The cycling conditions were 10 min polymerase activa-
tion at 95°C followed by 40 cycles at 95°C for 15 s and
60°C for 60 s. To calculate the cycle number at which
the desired transcript was detected (denoted CT), the
threshold was set above the non-template control back-
ground and within the linear phase of target gene
amplification.
Western blot analysis
Cell lysates were prepared as described previously [23].
Proteins were resolved by SDS-PAGE and transferred to
polyvinyldifluoride (PVDF) membranes (Immobilon).
The blots were blocked with 4% BSA for 1 h at room
temperature and then probed with rabbit anti-human
antibodies against MMP-2, p-IKKα/β, IKKα/β, p65, p-
p65, p-AMPK, AMPK, p-p38, or p38 (1:1000) each sep-
arately for 1 h at room temperature. After three washes,
the blots were incubated with peroxidase-conjugated
donkey anti-rabbit secondary antibody (1:1000) for 1 h
at room temperature. The blots were visualized by en-
hanced chemiluminescence using Kodak X-OMAT LS
film (Eastman Kodak, Rochester, NY, USA).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation analysis was performed
as described previously [24]. DNA immunoprecipitated
using the anti-p65 antibody was purified. The DNA was
then extracted with phenol-chloroform. The purified
DNA pellet was subjected to PCR. PCR products were
resolved by 1.5% agarose gel electrophoresis and visual-
ized by UV. The primers 5′-CCCCTGTTCAAGATGG
AGTC-3′ and 5′-CCCAGGTTGCTTCCTTACCT-3′ were
utilized in the PCR to amplify the human MMP-2 pro-
moter region (−673 to −517) [25].
Reporter assay
Human chondrosarcoma cells were transfected with a
reporter plasmid using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s recommendations. At
24 h after transfection, the cells were pretreated with in-
hibitors for 30 min, and then, CCL3 or vehicle was
added for 24 h. Cell extracts were then prepared, and lu-
ciferase and β-galactosidase activities were measured [3].
Immunofluorescence staining
Human chondrosarcoma cells were plated on 24-well
culture plates with coverslips. Cells were treated with
CCL3 (30 ng/ml) and washed twice with ice-cold
phosphate-buffered saline. Immunofluorescence staining
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formed as described previously [22].
Immunohistochemistry
The human chondrosarcoma tissue array was purchased
from Biomax (Rockville, MD, USA; 8 cases for normal
cartilage, 4 cases for type Ib chondrosarcoma, and 4
cases for type IIb chondrosarcoma). The tissues were
placed on glass slides, rehydrated, and incubated in 3%
hydrogen peroxide to block the endogenous peroxidase
activity. After trypsinization, sections were blocked by
incubation in 3% bovine serum albumin (BSA) in PBS.
The slides were incubated at 4°C overnight with a 1:50
diluted primary antibody, which was either monoclonal
mouse anti-human CCL3, CCR5, or MMP-2 antibody.
After being washed 3 times with PBS, samples were
treated with goat anti-mouse IgG biotin-labeled secondary
antibodies at a dilution of 1:50. The bound antibodies
were detected with an ABC kit (Vector Laboratories,
Burlingame, CA). The slides were stained with the chro-
mogen diaminobenzidine, washed, counterstained with
Delafield’s hematoxylin, dehydrated, treated with xylene,
and mounted. The intensity of staining was evaluated as 0,
1+, 2+, 3+, 4+, and 5+ for no staining, very weak staining,
weak staining, moderate staining, strong staining, and very
strong respectively. IHC score was determined as the sum
of the intensity score.
Statistics
Data are presented as mean ± standard error of the mean
(SEM). Statistical comparison of two groups was
performed using the Student’s t test. Statistical compari-
sons of more than two groups were performed using
one-way analysis of variance with Bonferroni’s post-hoc
test. Analyzing patterns of staining in immunohisto-
chemical studies statistical comparison of two tissue
scores was performed using the Regression Analysis
Method. In all cases, p < 0.05 was considered significant.
Results
Correlation of CCL3, CCR5, and MMP-2 expression in
human chondrosarcoma specimens
Previous study suggest that CCL3 is overexpressed in
many cancer types [26]. However, the expression of CCL3,
CCR5 and MMP-2 in chondrosarcoma is still unknown.
Therefore, we analyzed samples from chondrosarcoma
specimens by immunohistochemical staining. The expres-
sion of CCL3, CCR5, and MMP-2 in chondrosarcoma
specimens was significantly higher than that in normal
cartilage (Figure 1A-C). We also used western blotting
to confirm the results from immunohistochemistry that
the expression of CCL3 and MMP-2 in chondrosarcoma
was also significantly higher than that in chondrocytes
(Additional file 1: Figure S2). In addition, the high levelof CCL3 expression correlated strongly with CCR5 and
MMP-2 expression, which was also indicated by the
quantitative data (Figure 1D). Taken together, these re-
sults indicate that CCL3, CCR5, and MMP-2 expression
are correlated in human chondrosarcoma specimens.
Involvement of MMP-2 in CCL3-induced migration of
chondrosarcoma cells
It has been reported that CCL3 promotes tumor metas-
tasis [26]. We therefore directly examined migration in
human chondrosarcoma cell lines in response to CCL3
by using Transwell and wound-healing migration as-
says. CCL3 (3–100 ng/ml) induced cell migration and
wound healing migration of chondrosarcoma cells
(JJ012 & SW1353) in a concentration-dependent man-
ner (Figure 2A&B). On the other hand, incubation of
primary chondrocytes with CCL3 did not induce cell
migration (Additional file 1: Figure S3). We further
examine whether the JJ012 cells expressed high level of
CCL3. Indeed, we found that JJ012 expressed high level
of CCL3 than primary chondrocytes (Additional file 1:
Figure S4).
Previous studies have shown significant expression
levels of MMP-1, -2, -3, -9, and -13 in human chon-
drosarcoma cells [7,27]. We therefore hypothesized that
MMPs may be involved in CCL3-induced chondrosar-
coma migration. Incubation of cells with CCL3 increased
transcriptional expression of MMP-2 but not other
MMPs, as measured by qPCR (Figure 2C). In JJ012 cells,
CCL3 increased the expression of MMP-2 protein in a
time-dependent manner (Figure 2D; upper panel). MMP-
2 protein expression was also increased in the super-
natant, and its enzyme activity was upregulated (Figure 2D;
lower panel). To examine whether MMP-2 was involved
in CCL3-induced cell migration, both the MMP-2 inhibi-
tor and siRNA against MMP-2 were used. Pretreatment of
cells with the MMP-2 inhibitor or transfection with
MMP-2 specific siRNA abolished CCL3-induced cell mi-
gration and would healing activity (Figure 2E&F). To con-
firm that CCL3 mediates cell migration and MMP-2
expression in human chondrosarcoma cells, JJ012 cells
lines stably expressing CCL3 shRNA were established.
CCL3 expression in stable transfectants was compared
with that in controls by western blotting. The expression
of CCL3 was dramatically inhibited in JJ012/CCL3 shRNA
cells (Figure 2I). While the knockdown of CCL3 did not
affect JJ012 cell growth (data not shown), the migratory
ability of JJ012 cells was inhibited (Figure 2G&H) as evalu-
ated using Transwell assays and wound healing migration
assays. In addition, CCL3 knockdown also reduced MMP-
2 expression in JJ012 cells (Figure 2I). These results
indicate that CCL3 upregulates MMP-2 and migration
in chondrosarcoma cells, but not necessarily MMP-2
associated.
Figure 1 CCL3, CCR5, and MMP-2 expression correlates with the human chondrosarcoma specimens. Immunohistochemistry of CCL3 (A),
CCR5 (B), and MMP-2 (C) expression in normal cartilage and chondrosarcoma tissues. The correlative and quantitative data are shown in (D).
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Figure 2 CCL3-directed migration activity of human chondrosarcoma cells involves up-regulation of MMP-2. (A-B): Cells were incubated
with CCL3 for 24 h, and in vitro migration was measured either by Transwell (A) or by a wound-healing assay (B). (C): JJ012 cells were incubated
with CCL3 for 24 h, and MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13 mRNA levels were determined using qPCR. (D): JJ012 cells were incubated
with CCL3 for the indicated periods or with the indicated doses of CCL3, and cell lysates and supernatants were collected. MMP-2 protein levels
in cell lysates and enzymatic activity in supernatants were determined by western blotting and zymography. (E-F): JJ012 cells were transfected
with MMP-2 siRNA or were pre-treated with MMP-2 inhibitor, and in vitro migration was measured with the Transwell (E) or the wound-healing
assay (F). (G-H): In vitro migration activity of JJ012/control-shRNA and JJ012/CCL3-shRNA cells was measured with Transwell and wound-healing
assays. (I): The protein levels of CCL3 and MMP-2 of in JJ012 cells transfected with control-shRNA or CCL3-shRNA was measured by western
blotting. The results are expressed as the mean ± SE. *P < 0.05 compared with control. #P < 0.05 compared with CCL3-treated group.
Hsu et al. Cell Communication and Signaling 2013, 11:68 Page 7 of 15
http://www.biosignaling.com/content/11/1/68CCL3-mediated MMP-2 expression and cell migration are
via the CCR5 receptor
A previous study showed that CCL3 affects cell migration
through binding to the cell surface CCR5 receptor [28].
Pretreatment of cells with CCR5 mAb or the CCR5 recep-
tor inhibitor (Met-RANTES) reduced CCL3-induced cell
migration and invasion (Figure 3A-C) and inhibited
CCL3-induced the mRNA and protein expression of
MMP-2 (Figure 3D&E). Therefore, blocking CCR5 re-
duced CCL3-mediated cell migration and MMP-2 expres-
sion in human chondrosarcoma cells.
The AMPK-dependent p38 pathway is involved in the
CCL3-mediated cell migration and MMP-2 expression in
chondrosarcoma cells
AMPK activation has been reported to mediate tumor
cell migration [4,29]. We therefore used AMPK inhibi-
tors (Ara A and compound C) to examine whether
AMPK mediates CCL3-induced cell motility. Pretreat-
ment of cells for 30 min with Ara A (0.5 mM) and com-
pound C (10 μM) markedly attenuated CCL3-induced
migration, invasion, and MMP-2 expression (Figure 4A-
E). To determine the identity of the catalytic subunit of
AMPK that mediates CCL3 signaling in human chon-
drosarcomas, we performed a migration assay by using
cells transfected with siRNA specific for either AMPKα1
or AMPKα2. Transfection of cells with either AMPKα1
or AMPKα2 siRNA antagonized CCL3-induced cell mi-
gration and MMP-2 expression (Figure 4A&D). The data
therefore suggest that AMPKα1 and AMPKα2 are in-
volved in CCL3-mediated migration activity and MMP-2
expression in chondrosarcoma. Furthermore, incubation
of cells with CCL3 promoted AMPKα phosphorylation
at Thr172 in a time-dependent manner (Figure 4F).
AMPK-dependent p38 activation has been reported to
be involved in the metastasis of human chondrosarcoma
[30]. We investigated the role of p38 in mediating
CCL3-induced migration by using the specific p38 in-
hibitor SB203580. Pretreatment of cells with SB203580
(10 μM) or transfection of cells with the p38 mutant
abolished CCL3-induced migration, invasion, and MMP-
2 expression (Figure 5A-E). In addition, treatment of the
chondrosarcoma with CCL3 resulted in time-dependent
phosphorylation of p38 (Figure 5F). Moreover, pretreat-ment of cells with Ara A or compound C for 30 min
markedly inhibited CCL3-induced p38 phosphorylation
(Figure 5G). In contrast, pretreatment with SB203580
did not effect CCL3-mediated AMPK phosphorylation
(Figure 5H). Therefore, these results indicate that p38
may function as a signaling molecule downstream of
AMPK in CCL3-mediated cell migration and MMP-2
expression.
NF-κB signaling pathway is involved in CCL3-mediated
MMP-2 up-regulation and migration activity
CCL3 has been reported to induce cell migration
through NF-κB activation [31]. To examine whether NF-
κB activation was involved in CCL3-induced cell migra-
tion, an NF-κB inhibitor, PDTC, or the IκB protease
inhibitor, TPCK, were used. Figure 6A-E shows that pre-
treatment of cells with either PDTC or TPCK inhibited
CCL3-induced migration, invasion, and MMP-2 expres-
sion in chondrosarcoma cells. Therefore, CCL3 in-
creased cell migration and MMP-2 expression through
NF-κB pathway. We also examined the upstream mole-
cules involved in CCL3-induced NF-κB activation.
Stimulation of cells with CCL3 induced IKKα/β phos-
phorylation in a time-dependent manner (Figure 6F). In
addition, transfection with the IKKα or IKKβ mutants
markedly reduced CCL3-induced cell motility and MMP-2
expression (Figure 6A&D). These data suggest that activa-
tion of IKKα/β was involved in CCL3-induced cell motility
of human chondrosarcoma cells. Treatment of JJ012 cells
with CCL3 for various periods also resulted in p65 phos-
phorylation (Figure 6F). Pre-treatment of cells with CCR5
mAb, compound C, or SB203580 reduced CCL3-induced
p65 phosphorylation (Figure 6G).
Next we examine whether CCR5, AMPK, and p38 are
upstream molecules in CCL3-mediated NF-κB activa-
tion. CCL3 stimulation increased p65 binding to the
NF-κB element on the MMP-2 promoter by using chro-
matin immunoprecipitation assay (Figure 7A). This was
attenuated by pretreatment of cells with CCR5 mAb,
Ara A, SB203580, or PDTC (Figure 7A). In addition,
Met-RANTES, Ara A, compound C, or SB203580 also re-
duced CCL3-induced p65 translocation into the nucleus
and NF-κB-luciferase activity (Figure 7B & Additional file 1:
Figure S5A). On the other hand, co-transfection with p38,
Figure 3 CCL3 increases cell migration through the CCR5 receptor. (A-E): Cells were pretreated for 30 min with CCR5 mAb or Met-RANTES.
Subsequently, they were stimulated with CCL3 (30 ng/ml) for 24 h, and in vitro migration (A&B), invasion (C), and MMP-2 (D&E) expression were
measured using the Transwell assay, wound healing assay, qPCR, and western blotting. The results are expressed as the mean ± SE. *P < 0.05
compared with control. #P < 0.05 compared with CCL3-treated group.
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siRNA abolished CCL3-induced NF-κB luciferase activ-
ity (Additional file 1: Figure S5B). Taken together, these
data suggest that activation of the CCR5 receptor,
AMPK, and p38 are required for CCL3-induced NF-κB
activation in human chondrosarcoma cells.Discussion
With the advent of systemic chemotherapy in the manage-
ment of mesenchymal malignancies such as osteosarcoma
and Ewing’s sarcoma, there has been a dramatic increase
in the long-term survival of patients. In contrast, chondro-
sarcomas continue to have a poor prognosis owing to the
Figure 4 AMPK pathway mediates CCL3-induced migration in human chondrosarcoma cells. (A-E): Cells were pretreated for 30 min with
Ara A (0.5 mM) and compound C (10 μM) or transfected with AMPKα1 and AMPKα2 siRNA for 24 h, following which they were stimulated with
CCL3 (30 ng/ml) for 24 h, and in vitro migration (A&B), invasion (C), and MMP-2 (D&E) expression were measured with the Transwell assay,
wound healing assay, qPCR, and western blotting. (F): JJ012 cells were incubated with CCL3 for indicated time intervals, and p-AMPK expression
was examined by western blotting. Results are expressed as the mean ± SE. *P < 0.05 compared with control. #P < 0.05 compared with
CCL3-treated group.
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sarcoma shows a predilection for metastasis to the lungs
and hence it is important to investigate the potential tar-
gets for preventing chondrosarcoma metastasis.Immunohistochemical analyses revealed that the expres-
sion of CCL3 in chondrosarcoma patients was higher than
that in normal cartilages. In this study, we hypothesized
and investigated the paradigm that CCL3 may direct the
Figure 5 (See legend on next page.)
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Figure 5 AMPK-dependent p38 pathway is involved CCL3-induced migration and MMP-2 expression. (A-E): Cells were pretreated for
30 min with SB203580 (10 μM) or transfected with p38 mutant for 24 h. Subsequently, they were stimulated with CCL3 (30 ng/ml) for 24 h, and
in vitro migration (A&B), invasion (C), and MMP-2 (D&E) expression were measured with the Transwell assay, wound healing assay, qPCR, and
western blotting. (F): JJ012 cells were incubated with CCL3 for indicated time intervals, and p-AMPK expression was examined by western
blotting. (G&H): Cells were pretreated for 30 min with Ara A, compound C, or SB203580 followed by stimulation with CCL3. The p-p38 (G) and
p-AMPK (H) expression was measured by western blotting. Results are expressed as the mean ± SE. *P < 0.05 compared with control. #P < 0.05
compared with CCL3-treated group.
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of exogenous CCL3 promoted cell migration, invasion,
and wound healing activity in chondrosarcoma cells.
On the other hand, CCL3-induced MMP-2 expression
and cell motility were abolished by CCL3 shRNA. Our
data suggest that CCL3 increases MMP-2 expression
and subsequently promotes cell migration in human
chondrosarcoma cells. The mechanisms underlying CCL3-
induced increase in MMP-2 production and cell migration
are activation of the CCR5 receptor, AMPK, p38, and NF-κB
pathways.
As shown in previous studies, the CCR5 receptor is
present on the surface of tumor cells and is responsible
for CCL3-mediated cell motility [33]. In this study, immu-
nohistochemical staining revealed that high levels of
CCL3 expression strongly correlated with CCR5 expres-
sion in human chondrosarcoma patients. Pre-treatment
of chondrosarcoma cells with CCR5 mAb or inhibitor
blocked CCL3-induced cell migration and reduced MMP-
2 expression. Therefore, the CCL3-CCR5 interaction me-
diated the migratory activity in human chondrosarcoma
cells.
Metastasis occurs in multiple steps. Tumor cells degrade
the basement membrane, mainly through the use of
MMPs [34]. In human cancer cells, MMP-1, MMP-2,
MMP-3, MMP-9, and MMP-13 have been found to be
correlated with malignant grade and metastasis [4,35]. On
the other hand, activation of MMPs is also involved in
CCL3-mediated cell motility [36]. In this study, we found
that while CCL3 induced MMP-2 expression and secre-
tion in human chondrosarcoma cells, treatment of cells
with the MMP-2 inhibitor reduced CCL3-induced cell mi-
gration. Moreover, inhibition of CCL3-enhanced MMP-2
protein expression, and siRNA knockdown of CCL-3 sig-
nificantly suppressed CCL3-induced migration. Therefore,
MMP-2 may be the CCL3-responsive mediator, and may
degrade the ECM leading to subsequent cancer migration
and metastasis.
AMPK is a heterotrimeric serine/threonine kinase
composed of a catalytic subunit, α, and regulatory β and
γ subunits [37]. Previous studies have shown that AMPK
is involved in the CCL3 signaling pathway [38]. We ob-
served that the AMPK inhibitors, namely, Ara A and
compound C, antagonize CCL3-mediated cancer migra-
tion and MMP-2 expression, suggesting that AMPKactivation is an obligatory event in CCL3-induced migra-
tion activity in these cells. We attempted to determine
the identity of the catalytic subunit of AMPKα1 or
AMPKα2, which mediates CCL3 signaling in human
chondrosarcoma cells. We found that siRNA against both
AMPKα1 and AMPKα2 reduce CCL3-mediated cancer
migration, implying that AMPKα1 and AMPKα2 are
involved in CCL3-induced migration activity. While
adiponectin-mediated prostate cancer migration has been
reported to be mediated by AMPKα1 but not AMPKα2
activation, [39] both AMPKα1 and AMPKα2 activation
have been reported to mediate adiponectin-induced cell
metastasis in human chondrosarcoma [30]. These data in-
dicate that AMPKα1 and AMPKα2 are important for me-
tastasis of human chondrosarcoma. Since it has also been
reported that AMPK interacts with p38 to regulate cell
motility in human chondrosarcoma [30], we examined the
potential role of p38 in the signaling pathway of CCL3-
induced migration activity. Pre-treatment of chondro-
sarcoma cells for 30 min with SB203580 or transfection
with the p38 mutant for 24 h markedly attenuated the
CCL3-induced migration activity and MMP-2 expres-
sion. In addition, we observed that treatment of chon-
drosarcoma cells with CCL3 induced increased p38
phosphorylation. These effects were inhibited by Ara A
or compound C. In contrast, the p38 inhibitor did not
affect CCL3-promoted AMPK phosphorylation, indicat-
ing the involvement of AMPK-dependent p38 activation
in CCL3-mediated migration and MMP-2 expression.
Tumor metastasis is the spread of tumor cells from a
primary tumor to colonize other sites of the body. Inva-
sion, intravasation, extravasation through the circulatory
system, colonization, and finally angiogenesis at a distant
site are the most common features of tumor metastasis.
Because of the prevalence of distant metastasis in pa-
tients with chondrosarcoma, prognosis is generally very
poor and the development of anti-metastatic therapy
could be useful for these patients. Here, we found that
CCL3 induced MMP-2 expression and subsequently
promoted migration in human chondrosarcoma through
activation of the CCR5 receptor, AMPK, p38, and NF-κB
signaling pathways (Figure 7C). These observations may
provide a better understanding of the mechanisms of
metastasis and may lead to the development of effective
therapies for chondrosarcoma.
Figure 6 CCL3 induces cells migration and MMP-2 upregulation through NF-κB. (A-E): Cells were pretreated for 30 min with PDTC (10 μM) and
TPCK (3 μM) or transfected with IKKα and IKKβ mutant for 24 h following which they were stimulated with CCL3 (30 ng/ml) for 24 h, and in vitro
migration (A&B), invasion (C), and MMP-2 (D&E) expression were measured with the Transwell assay, wound healing assay, qPCR, and western
blotting. (F): JJ012 cells were incubated with CCL3 for indicated time intervals, and p-IKK or p-p65 expression was examined by western blotting.
(G): Cells were pretreated for 30 min with CCR5 mAb, compound C, or SB203580, and subsequently stimulated with CCL3. The p-p65 expression was
measured by western blotting. Results are expressed as the mean ± SE. *P < 0.05 compared with control. #P < 0.05 compared with CCL3-treated group.
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Figure 7 The CCR5/AMPK/p38 pathway is involved in CCL3-mediated NF-κB activation. (A): JJ012 cells were pre-treated with CCR5 mAb,
Ara A, SB203580, or PDTC followed by stimulation with CCL3 for 120 min and analyses using the chromatin immunoprecipitation assay.
Chromatin was immunoprecipitated with anti-p65 antibody. One percentage of the precipitated chromatin was assayed to verify equal loading
(input). (B): JJ012 cells were pretreated with Met-RANTES, Ara A, compound C, or SB203580 followed by stimulation with CCL3 for 120 min, and
p65 immunofluorescence staining was performed. *P < 0.05 compared with control. #P < 0.05 compared with CCL3-treated group. (C): Schematic
diagram of the signaling pathways involved in CCL3-mediated enhanced cell migration in human chondrosarcoma cells. CCL3 increases MMP-2
expression and cell migration through the CCR5 receptor, AMPK, p38, and NF-κB signaling pathways.
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Additional file 1: Figure S1. AMPKα1 or AMPKα2 siRNA inhibited
AMPKα1 or AMPKα2 expression. JJ012 cells were transfected with
AMPKα1 or AMPKα2 siRNA for 24 h, the AMPKα1 or AMPKα2 expression
was examined by western blotting. Figure S2. CCL3 and MMP-2
expression in chondrocyte and chondrosarcoma. Western blotting results
of CCL3 and MMP-2 expression in chondrocytes and chondrosarcomas.
Figure S3. CCL3 did not induce cell migration in primary chondrocytes.
Primary chondrocytes were incubated with CCL3 for 24 h, and in vitro
migration was measured by Transwell. The results are expressed as the
mean ± SE. Figure S4. JJ012 expressed high level of CCL3 than
chondrocytes. The protein levels of CCL3 in JJ012 cells and primary
chondrocytes was measured by western blotting. Figure S5. CCR5,
AMPK, and p38 signaling pathways are involved in CCL3-induced NF-κB
activation. JJ012 cells were pretreated with CCR5 mAb, Met-RANTES, Ara
A, compound C, SB203580, PDTC, and TPCK for 30 min (A) or were
transfected with control siRNA, AMPKα1 siRNA, AMPKα2 siRNA, p38
mutant, IKKα mutant, or IKKβ mutant (B) before exposure to CCL3. NF-κB
luciferase activity was measured, and the results were normalized to the
β-galactosidase activity and expressed as the mean ± SE for three
independent experiments performed in triplicate. *P < 0.05 compared
with control. #P < 0.05 compared with CCL3-treated group.
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